Evidence map›Paper›PMID 42851795›Full record

ArticleAllergologie select2026

Dupilumab improves long-term asthma control in German patients with severe asthma: Real-world data.

Andreas Renner, Slagjana Stoshikj, Eckard Hamelmann, Dirk Skowasch, Christian Schulz, Margret Jandl, Olaf Schmidt, Katrin Milger, Rainer Ehmann, Christian Taube and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergologie select, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Andreas RennerDepartment of Pneumology, Medical University of Vienna, Vienna, Austria.
Slagjana StoshikjDepartment of Pneumology, Medical University of Vienna, Vienna, Austria.
Eckard HamelmannKinderzentrum Bethel, Evangelisches Klinikum Bethel, University Bielefeld, Bielefeld.
Dirk SkowaschDepartment of Internal Medicine II - Pneumology, University Hospital Bonn, Bonn.
Christian SchulzDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg.
Margret JandlHamburger Institut für Therapieforschung GmbH, Hamburg.
Olaf SchmidtPneumologische Gemeinschaftspraxis und Studienzentrum KPPK, Koblenz, Germany.
Katrin MilgerDivision of Respiratory Medicine, Lung Research Cluster, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Rainer EhmannAmbulante Pneumologie mit Allergiezentrum, Stuttgart.
Christian TaubeDepartment of Pulmonary Medicine, University Hospital Essen - Ruhrlandklinik, Essen.
Stephanie KornDepartment of Pulmonary and Respiratory Critical Care Medicine, Thoraxklinik Heidelberg und IKF Pneumologie Mainz, and.
Roland BuhlPulmonary Department, Mainz University Hospital, Mainz, Germany.
Marco IdzkoDepartment of Pneumology, Medical University of Vienna, Vienna, Austria.
German Asthma Net (GAN) study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDupilumab has proven effective in severe asthma, but there is only sparse evidence on its impact on asthma control in a real-world setting. MATERIALS AND

methodsAll patients from the German Asthma Net (GAN) severe asthma registry who initiated dupilumab after inclusion into the registry were analyzed. Clinical effectiveness was evaluated in those with at least 2 follow-up visits, with a maximum follow-up time of 3 years.

resultsA total of 481 patients with severe asthma initiated dupilumab. At baseline, median blood eosinophil count was 174 cells/µL (IQR 61.2 - 436); 184 (38.3%) were former smokers with median 9.6 pack-years (IQR 4.3 - 23.3). Clinical effectiveness was evaluated in 235 patients. The FEV

conclusionIn this large real-life study of dupilumab in patients with severe asthma dupilumab showed long-term clinical effectiveness for up to 3 years, with results consistent with prior randomized controlled trials.

Indexed as

airway inflammationbiologicsmonoclonal antibody treatmentreal-life datasevere asthma

Identifiers

PMID42851795
PMCPMC13647249

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.